Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain

Author:

Argüelles-Arias Federico1,Bermejo Fernando2,Borrás-Blasco Joaquín3,Domènech Eugeni4,Sicilia Beatriz5,Huguet José M.6,de Arellano Antonio Ramirez7,Valentine William J.8,Hunt Barnaby9ORCID

Affiliation:

1. Hospital Universitario Virgen Macarena, Seville, Spain; Facultad de Medicina, Universidad de Sevilla, Seville, Spain

2. Hospital Universitario de Fuenlabrada, Instituto de Investigación Sanitaria del Hospital La Paz (IdiPAZ), Madrid, Spain

3. Hospital de Sagunto, Valencia, Spain

4. Hospital Universitari Germans Trias i Pujol, Badalona, Spain; CIBEREHD, Madrid, Spain

5. Hospital Universitario de Burgos, Burgos, Spain

6. Hospital General Universitario de Valencia, Valencia, Spain

7. HEOR, Vifor Pharma Group, Glattbrugg, Switzerland

8. Ossian Health Economics and Communications GmbH, Basel, Switzerland

9. Ossian Health Economics and Communications GmbH, Bäumleingasse 20, 4051 Basel, Switzerland

Abstract

Background: Iron deficiency anemia (IDA) is a common complication of inflammatory bowel disease (IBD) and can result in reduced quality of life and increased healthcare costs. IDA is treated with iron supplementation, commonly with intravenous iron formulations, such as ferric carboxymaltose (FCM), and iron sucrose (IS). Methods: This study assessed the cost-effectiveness of FCM compared with IS, in terms of additional cost per additional responder in patients with IDA subsequent to IBD in the Spanish setting. An economic model was developed to assess the additional cost per additional responder, defined as normalization or an increase of ⩾2 g/dl in hemoglobin levels, for FCM versus IS from a Spanish healthcare payer perspective. Efficacy inputs were taken from a randomized controlled trial comparing the two interventions (FERGIcor). Costs of treatment were calculated in 2021 Euros (EUR) using a microcosting approach and included the costs of intravenous iron, healthcare professional time, and consumables. Cost-effectiveness was assessed over one cycle of treatment, with a series of sensitivity analyses performed to test the robustness of the results. Results: FCM was more effective than IS, with 84% of patients achieving a response compared with 76%. When expressed as number needed to treat, 13 patients would need to switch treatment from IS to FCM in order to achieve one additional responder. Costs of treatment were EUR 323 with FCM compared with EUR 470 with IS, a cost saving of EUR 147 with FCM. Cost savings with FCM were driven by the reduced number of infusions required, resulting in a reduced requirement for healthcare professional time and use of consumables compared with the IS arm. Conclusion: The present analysis suggests that FCM is less costly and more effective than IS for the treatment of IDA subsequent to IBD in Spain and therefore was considered dominant.

Funder

Vifor Pharma

Publisher

SAGE Publications

Subject

Gastroenterology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3